Artelo Biosciences, Inc. financial data

Symbol
ARTL on Nasdaq, ATLEW on OTC
Location
505 Lomas Santa Fe, Suite 160, Solana Beach, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 52.8 % -93.6%
Debt-to-equity 1.05K % +9244%
Return On Equity -3.4K % -3156%
Return On Assets -297 % -216%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.02M shares -37.5%
Common Stock, Shares, Outstanding 1.56M shares -51.8%
Entity Public Float 4.29M USD -23.8%
Common Stock, Value, Issued 2K USD -33.3%
Weighted Average Number of Shares Outstanding, Diluted 787K shares +46.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 7.01M USD +24.2%
General and Administrative Expense 5.42M USD +39.3%
Operating Income (Loss) -12.4M USD -30.3%
Nonoperating Income (Expense) -61K USD -115%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -12.5M USD -36.9%
Earnings Per Share, Diluted -20 USD/shares -89%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.64M USD -63%
Marketable Securities, Current 0 USD -100%
Assets, Current 1.83M USD -63.4%
Operating Lease, Right-of-Use Asset 73K USD -32.4%
Intangible Assets, Net (Excluding Goodwill) 2.04M USD 0%
Other Assets, Noncurrent 3K USD
Assets 4.27M USD -40.2%
Accrued Liabilities, Current 46K USD
Liabilities, Current 4.86M USD +597%
Operating Lease, Liability, Noncurrent 40K USD -48.7%
Liabilities 4.9M USD +532%
Accumulated Other Comprehensive Income (Loss), Net of Tax -277K USD -27.1%
Retained Earnings (Accumulated Deficit) -58.8M USD -26.9%
Stockholders' Equity Attributable to Parent -633K USD -110%
Liabilities and Equity 4.27M USD -40.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.6M USD +45.7%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 500M shares +900%
Common Stock, Shares, Issued 1.56M shares -51.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.59M USD +1.73%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.72M USD -60.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 5.68M USD +10.6%
Operating Lease, Liability 87K USD +1350%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -12.6M USD -37.3%
Operating Lease, Liability, Current 39K USD +14.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 69.4K shares -83.3%
Additional Paid in Capital 58.5M USD +10.5%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 111K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%